Core Viewpoint - The company has announced the achievement of conditions for the first unlock period of the reserved stock grant and the second unlock period of the initial stock grant under the 2023 restricted stock incentive plan, allowing 71 incentive recipients to unlock a total of 4,826,000 shares, which represents 0.63% of the company's total share capital [1][2][18]. Summary by Relevant Sections Incentive Plan Overview - The 2023 restricted stock incentive plan initially granted 21,370,000 shares, accounting for approximately 2.74% of the company's total share capital at the time of the plan's announcement [2][11]. - The plan includes a reserved grant of 1,000,000 shares, representing 0.13% of the total share capital [2][11]. Unlock Conditions - A total of 71 incentive recipients are eligible for unlocking, with 70 recipients eligible for the second unlock period of the initial grant (4,326,000 shares) and 11 recipients eligible for the first unlock period of the reserved grant (500,000 shares) [1][2][18]. - The unlocking of shares is subject to the completion of necessary procedures by relevant authorities [1][2]. Performance Assessment - The performance assessment for the first unlock period requires a net profit growth rate of no less than 155% for 2023, based on the 2022 net profit [7][9]. - For the second unlock period, the required growth rate is 78% for 2024, and for the third unlock period, it is 131% for 2025 [9][10]. Compliance and Approval - The board of directors and the supervisory board have reviewed and approved the unlocking conditions, confirming compliance with relevant regulations and the company's articles of association [22][23]. - Legal opinions affirm that the necessary approvals and authorizations have been obtained for the unlocking of shares [24][25].

证券代码：300627 证券简称：华测导航 公告编号：2025-061 上海华测导航技术股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 上海华测导航技术股份有限公司（以下简称"公司"）第四届监事会第十七 次会议的通知于2025年7月2日以书面或电子邮件的形式发出，会议于2025年7月 合通讯方式召开。本次会议应出席监事3名，实际出席监事3名。本次会议由沈礼 伟先生主持，公司部分高级管理人员列席了本次会议。 本次会议的召开和表决程序符合《中华人民共和国公司法》等有关法律、行 政法规、部门规章、规范性文件和《上海华测导航技术股份有限公司章程》的规 定。 二、监事会会议审议情况 经与会监事审议，以记名投票表决方式通过如下议案： 股票激励计划授予数量和授予价格》的议案。 经公司第四届监事会全体监事审议，一致认为公司2024年年度权益分派已于 法规、规范性文件和公司《2021年限制性股票激励计划（草案）》的规定，对2021 年限制性股票激励计划限制性股票的授予数量和授予价格进行调整，符合公司和 全体股东的利益，不存在损害中小股东合法 ...

Core Viewpoint - The company has adjusted the exercise price of its stock option incentive plans for 2021 and 2022, following the implementation of annual profit distribution, which will not materially affect its financial status and operational results [17][18]. Summary by Sections Stock Option Incentive Plan Approval Process - The 2021 stock option incentive plan involved granting 1.8 million stock options, with an initial exercise price set at 123.72 yuan per share [2]. - The number of initial grantees was adjusted from 161 to 159 due to two employees leaving the company, while the total number of options remained unchanged at 1.8 million [3]. Adjustments to Stock Options - The exercise price for the 2021 stock option plan was adjusted from 123.72 yuan to 82.44 yuan per share due to a rights issue, increasing the number of options from 1,452,600 to 2,178,149 [4]. - The 2022 stock option plan initially set an exercise price of 124.23 yuan per share, which was later adjusted to 65.22 yuan per share, with the number of options increasing from 1,734,400 to 3,295,360 [13]. Impact of Adjustments - The adjustments to the exercise prices of stock options are in accordance with the company's rights distribution and will not have a significant impact on the company's financial condition or operational results [17][18]. Legal Opinions - Legal opinions confirm that the adjustments to the stock option plans for both 2021 and 2022 have received the necessary approvals and comply with relevant regulations [18].

Core Viewpoint - The legal opinion letter addresses the adjustments to the restricted stock incentive plans of Wuhan Lingdian Automotive Control System Co., Ltd., including changes in grant prices, vesting periods, and the conditions for vesting of the stock options [1][2][3]. Summary by Relevant Sections Adjustments to Incentive Plans - The company has adjusted the grant prices for the 2021 and 2023 restricted stock incentive plans, with the adjusted prices being 35.415 CNY per share for the 2021 plan and 40.075 CNY per share for the 2023 plan [7][8]. - The adjustments were made in accordance with the company's incentive plan regulations and relevant legal frameworks [8][17]. Vesting Conditions and Periods - The 2021 incentive plan's third vesting period is from August 5, 2024, to August 4, 2025, while the second vesting period for the reserved grants is from August 1, 2024, to July 31, 2025 [9][13]. - The 2023 incentive plan's first vesting period is from October 11, 2024, to October 10, 2025 [15]. Achievement of Vesting Conditions - For the 2021 plan, the vesting conditions include the absence of negative audit opinions and the fulfillment of performance targets, with the company achieving a revenue of 100,848.11 million CNY in 2023, representing a 32.27% increase compared to 2020 [11][14]. - The 2023 plan also requires similar conditions, with the company meeting the necessary performance metrics for vesting [14][15]. Stock Cancellation - A total of 831,012 shares of restricted stock were canceled due to various reasons, including the departure of 122 incentive recipients and failure to meet performance targets [16][17]. - The cancellation aligns with the stipulations outlined in the incentive plans and relevant regulations [16][17].

预留授予第一个归属期归属条件成就的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-044 广州迈普再生医学科技股份有限公司 重要内容提示： 公司总股本（剔除回购股份，下同）0.07%； 股（调整后）； 象定向发行的本公司人民币 A 股普通股股票； 后、上市流通前，公司将发布相关提示性公告，敬请投资者关注。 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2025 关于 2023 年限制性股票激励计划 预留授予部分第一个归属期归属条件成就的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 年 7 月 7 日召开第三届董事会第十一次会议，审议通过了《关于 2023 预留授予第一个归属期归属条件成就的公告 年限制性股票激励计划预留授予部分第一个归属期归属条件成就的 议案》，现将有关事项公告如下： 一、2023 年限制性股票激励计划实施情况概要 议通过了《关于 <广州迈普再生医学科技股份有限公司 ensp="ensp" 年限制性="年限制性"> 股票激励计划（草案）>及其摘要的议案》等议案，《公司 2023 年限 制性股票激励计划》（ ...

Core Points - The company Shanghai Xianhui Automation Technology Co., Ltd. has announced the results of its stock option exercise and the listing of shares related to its equity incentive plan [1][6] - A total of 429,089 shares will be listed for trading on July 10, 2025, following the exercise of stock options by 354 participants [6][9] - The exercise price for the stock options was set at 37.76 yuan per share, resulting in total investment of approximately 16.20 million yuan [9] Summary by Sections Stock Option Exercise and Listing - The stock options exercised are part of the company's equity incentive plan, with a total of 429,089 shares to be listed [1] - The listing date for these shares is July 10, 2025 [1][6] Decision-Making Process - The board of directors and the supervisory board have approved the stock option incentive plan and its related matters [2][3] - Independent directors have expressed their agreement with the plan, confirming its legality and alignment with shareholder interests [3] Adjustments to the Incentive Plan - The initial number of stock options granted was adjusted from 2,900,440 to 2,812,320 due to some participants leaving or voluntarily giving up their options [3] - The exercise price was adjusted from 54.00 yuan to 38.36 yuan, and later to 38.06 yuan [4][5] Impact on Share Capital - Following the exercise, the company's total share capital will increase from 125,050,244 shares to 125,479,333 shares [6][9] - The newly issued shares represent 0.34% of the total share capital prior to the exercise [9] Financial Reporting - The recent financial metrics indicate that the company's earnings per share were 0.47 yuan, and the net asset value per share was 16.14 yuan before the exercise [9] - The exercise of stock options is not expected to have a significant impact on the company's financial status or operational results [9]

证券代码：000534 证券简称：万泽股份 公告编号：2025-062 万泽实业股份有限公司 监事会关于公司 2025 年股权激励计划 首次授予激励对象名单的审核意见及公示情况说明 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 万泽实业股份有限公司（以下简称"公司"）于2025年6月27日召开第十 一届董事会第四十九次会议及第十一届监事会第二十九次会议，审议通过 了《 <公司2025年股权激励计划 草案="草案"> 及其摘要的议案》等议案，并于 信息披露网站上披露了相关公告。 根据中国证监会、深圳证券交易所（以下简称"证券交易所" ）的规范 要求、 《上市公司股权激励管理办法》 务； 异议或不良反映，无反馈记录。 （二）核查方式 公司监事会核查了本次激励计划拟首次授予激励对象的名单、身份证 件、其与公司（含合并报表子公司，下同）签订的劳动合同或聘用协议以及 其在公司担任的职务及其任职文件等资料。 （以下简称" 《管理办法》 "）和《公司 章程》等相关规定，公司对2025年股权激励计划（以下简称"本次激励计划"） 首次授予激励对象名单的姓名和职务在公司内部进行 ...

Core Points - The company announced the fulfillment of vesting conditions for the first grant of the 2021 and 2023 restricted stock incentive plans, totaling 418,257 shares [1][24] - The 2021 incentive plan includes a total of 2,398,250 shares, with 1,918,600 shares granted initially and 479,650 shares reserved [2][24] - The 2023 incentive plan involves 1,353,647 shares, with 1,095,597 shares granted initially and 258,050 shares reserved [13][24] Summary by Sections 1. Incentive Plan Overview - The 2021 incentive plan was approved with a total grant of 2,398,250 shares, representing 4.65% of the company's total share capital as of the announcement date [2] - The 2023 incentive plan was approved with a total grant of 1,353,647 shares, representing 2.61% of the company's total share capital as of the announcement date [13] 2. Vesting Conditions - For the 2021 plan, the vesting schedule includes five periods with specific performance targets based on revenue growth rates ranging from 12% to 80% [3][4] - The 2023 plan has a similar structure, with vesting periods and performance targets set at 30% to 50% for the first two periods and 40% for the third period [13][15] 3. Grant Details - The adjusted grant price for the 2021 plan is 35.85 CNY per share, while the adjusted grant price for the 2023 plan is 40.075 CNY per share [2][13] - The number of participants in the 2021 plan is 221 for the initial grant and 45 for the reserved grant, while the 2023 plan includes 326 participants for the initial grant and 69 for the reserved grant [2][13] 4. Approval and Implementation - The board of directors and supervisory board have reviewed and approved the vesting conditions for the 2021 and 2023 plans, confirming that the conditions have been met for the specified shares [24][25] - The company has conducted internal reviews and public disclosures regarding the incentive plans and compliance with regulations [6][20]

Core Viewpoint - The company has successfully completed the conditions for the 2025 Restricted Stock Incentive Plan, with the granting of restricted stocks to eligible participants confirmed on June 9, 2025 [1] Group 1: Incentive Plan Details - The company held meetings on June 9, 2025, to approve adjustments to the list of incentive recipients, the number of shares granted, and the grant price [1] - A total of 432,250 shares of restricted stock will be granted to 667 eligible participants [1] - The plan is part of the company's strategy to incentivize and retain key personnel [1] Group 2: Payment and Stock Allocation - As of June 20, 2025, 644 participants completed the payment for the restricted stock, totaling RMB 98,776,272 [2] - 23 participants voluntarily forfeited a total of 179,200 shares due to personal reasons [2] - The total number of restricted stocks granted to the remaining participants is 4,143,300 shares, sourced from the company's repurchased A-shares [2] Group 3: Share Capital Structure - Before the stock grant, the company had 5,473,686 restricted shares and 1,803,114,002 unrestricted shares, totaling 1,808,587,688 shares [3] - After the grant, the number of restricted shares will increase to 9,616,986, while unrestricted shares will decrease to 1,798,970,702 [3] - The final share capital structure will be confirmed after the completion of the registration process with the China Securities Depository and Clearing Corporation [3]

Group 1 - The company is proposing a stock option incentive plan for 2025 to attract and retain talent, aligning the interests of shareholders, the company, and core team members [5][6][8] - The stock option incentive plan has been approved by the company's board and supervisory committee and is now submitted for shareholder approval [6][8] - The company will conduct the shareholder meeting on July 14, 2025, with both on-site and online voting options available [5][7] Group 2 - The company plans to change its name from "Jiangsu Aidea Pharmaceutical Co., Ltd." to "Jiangsu Aidea Pharmaceutical Group Co., Ltd." to enhance group management and resource utilization [12][13] - The name change aligns with the company's strategic development needs and will not adversely affect its operations or shareholder interests [13][14] - The company will also revise its articles of association to reflect the name change and will seek necessary approvals for the changes [14][22] Group 3 - The company intends to adjust its fundraising investment projects, specifically changing the focus from "Ustectidine New Indication Research Project" to "Integrase Inhibitor Drug Research and Clinical Study Project" [16][19] - The total amount of funds to be redirected is approximately 84.37 million yuan, which will be fully allocated to the new project [15][19] - The integrase inhibitor project aims to develop a new generation of anti-HIV drugs and has shown promising results in initial clinical trials [20][21] Group 4 - The company is proposing the appointment of a new independent director candidate, Hu Wenyuan, following the resignation of the previous independent director [11][12] - The nomination has been approved by the board and is now subject to shareholder approval [11][12] - The company is also seeking to fill a vacancy in the supervisory board due to the resignation of a non-employee representative supervisor [22][23]